Insider Purchases: Inside the Buy

Tag: Clinical stage biotech

A biotech laboratory where scientists examine glowing neurons and retinal cells while investors, institutional funds, and short sellers watch a countdown clock labeled

🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough

Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.

Read entire article

Tags: annexon, annexon biosciences, AnnexonBiosciences, annx, annx stock, BiotechStocks, buy or sell ANNX, c1q, clinical stage biotech, complement pathway, featured-insiders, funanc1al, FUNanc1al Biotech, FUNanc1al Investing, geographic atrophy, growth stocks, guillain barre syndrome, healthcare investing, healthcare stocks, hub-insiders, insider buying, InsiderBuying, MuneerSatter, Neuroinflammation, Phase3Data, risks buying ANNX, short squeeze, ShortSqueeze, tanruprubart, vonaprument, why buy ANNX